SAN FRANCISCO, Sept. 15 The Gladstone Center for Translational Research and the California Institute for Quantitative Biomedical Research (QB3) at the University of California, San Francisco (UCSF) together with Collaborative Drug Discovery, Inc. (CDD) are pleased to announce the prestigious speakers and panelists that will present at the 3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research. The meeting is on October 1st, 2009 from 8:30 am - 6:30 pm on the first floor Gladstone Institute Auditorium at the UCSF, Mission Bay Campus (San Francisco, CA, USA) and it is free and open to the general public (see below for registration instructions).
Confirmed speakers and panelists include:
Following in the footsteps of our previous two community meetings, we expect this will be an informative, scientifically focused meeting with the opportunity to informally interact with biomedical research scientists from across a wide range of therapeutic areas and specialties including neglected infectious disease research and leading commercial research of interest to biotech and pharmaceutical companies.
There will be two round table panel discussions, one focused on biotech research and a second that brings together academics, pharma industry, non-profit and NIH researchers to discuss topics related to drug discovery and fostering collaboration between research groups. We will also have a poster session for attendees to present their work and several networking opportunities including a post meeting reception.
Dr. Sean Ekins (CDD Collaborations Director), who will be chairing the biotech panel, mentioned, "It is unusual to have thought leaders like these coming together, especially at a free, open symposium for the general public. With posters and networking sessions, this provides a unique forum for scientists interested in commercial and humanitarian drug discovery R&D. We encourage scientists and drug discovery business leaders to attend, interact and find out about the research being done by our keynote speakers, while at the same time learning about how the CDD platform can help scientists archive, mine and collaborate around their data." CDD scientists will also present their research, provide training, software vision and a development roadmap for the CDD database.
"CDD will showcase new capabilities to the public for the first time, including the secure CDD Vault(TM) for handling sensitive, private data, CDD Collaborate(TM) for private-to-private collaborations with new selective projects views, and CDD Public(TM) which is a constantly growing and more useful set of public data to complement folks private R&D," Barry Bunin, PhD (CDD President) said. "Each year the community meeting gets bigger and more exciting as CDD's extended community grows, so please join us to help make this the best meeting yet. Given it is a community based platform, it is more about the scientists involved and we are here to facilitate and help."
The 3rd Annual community meeting is free thanks to sponsorship from ASINEX, additional sponsorship opportunities are still available for a limited number of partners (contact email@example.com).
Self-register for free at the following URL: https://www.acteva.com/go/cdd
To present a poster email the poster title and abstract to firstname.lastname@example.org
About Collaborative Drug Discovery, Inc.
Collaborative Drug Discovery, Inc. (CDD) provides web-based software platform that organizes preclinical research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to "archive, mine, and collaborate"(R) around preclinical chemical and biological drug discovery data through a web-based interface. The platform is composed of 3 components, CDD Vault(TM) for securely storing and handling sensitive, private data, CDD Collaborate(TM) for enabling secure private-to-private collaborations with new selective projects views, and CDD Public(TM) which is a set of growing public datasets from the scientific community. The software can be used for example to help distributed research groups to safely store and intelligently analyze small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens. Scientists can choose which datasets to keep completely private and which datasets, if any, to share securely with selected colleagues. Unique collaboration features and CDD's community-oriented approach help unite globally dispersed humanitarian efforts against neglected infectious diseases. Similar collaborative strategies are also rapidly gaining prominence in the commercial arena. CDD offers its industrial-strength database software at a price affordable to academic laboratories, research foundations, and small companies. For more information, visit http://www.collaborativedrug.com.
-- Christopher Lipinski, PhD, Melior Discovery, Adjunct Senior Research Fellow (ret.), Pfizer -- Ken Duncan, PhD, Senior Program Officer, Bill & Melinda Gates Foundation -- Chris Waller, PhD, Senior Director of Precompetitive Collaborations, Pfizer -- Tanya Parish, PhD, Acting Director of Drug Discovery, IDRI; Professor of Mycobacteriology, Queen Mary's School of Medicine -- Clifton Barry, PhD, Senior Investigator, NIAID/NIH -- Takushi Kaneko, PhD, Senior Project Leader, Chemistry, TB Alliance -- Andrea Altieri, PhD, Manager, Marketing & Project Development, ASINEX -- Biotech Panel: Bard Geesaman (PharmSelex), Ellen Berg (Bioseek), Marc Navre (Ardelyx), Christopher Silvia (Icagen)
SOURCE Collaborative Drug Discovery